Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from CalciMedica ( (CALC) ).
On November 6, 2025, CalciMedica, Inc. announced an increase in the maximum aggregate offering price of its common stock from $4,450,000 to $9,700,000 under its at-the-market offering agreement with H.C. Wainwright & Co. This adjustment reflects the company’s strategic move to bolster its financial resources, potentially enhancing its market position and providing greater flexibility in pursuing its operational goals.
The most recent analyst rating on (CALC) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on CalciMedica stock, see the CALC Stock Forecast page.
Spark’s Take on CALC Stock
According to Spark, TipRanks’ AI Analyst, CALC is a Underperform.
CalciMedica’s low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.
To see Spark’s full report on CALC stock, click here.
More about CalciMedica
CalciMedica, Inc. operates in the biotechnology industry, focusing on developing therapies for acute inflammatory diseases.
Average Trading Volume: 51,375
Technical Sentiment Signal: Sell
Current Market Cap: $42.62M
See more data about CALC stock on TipRanks’ Stock Analysis page.